ClinicalTrials.gg

Program

HLX37

A development code. Also written as “Investigational drug: HLX37 dose1, IV, Q3W” and “Investigational drug: HLX37 dose2, IV, Q3W”.

In Fosun Pharma's pipeline, PD-L1 x VEGF. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Fosun Pharma.

Furthest: phase 3, since Oct 4, 20262 company-led studies, 2 open or runningNext primary completion: Mar 30, 2027 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma22 open or runningphase 3since Oct 4, 2026Nov 28, 2025Mar 30, 2027early phase 1 · NCT07274813
  • Named in Fosun Pharma’s own pipeline as HLX37 (PD-L1 x VEGF), phase 1, as of Sep 21, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 28, 2025First study: early phase 1 study in Advanced/Metastatic Solid TumorsFirst studyNCT07274813 · 254 planned · China
  2. Oct 4, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungPhase 3 reachedNCT07865910 · 1,438 planned · China

Ahead

  1. Mar 30, 2027Primary completion: early phase 1 study in Advanced/Metastatic Solid TumorsNCT07274813
  2. Dec 30, 2030Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07865910

TargetBeta

“PD-L1 x VEGF”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
pumitamigBioNTechphase 334

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07865910Carcinoma, Non-Small-Cell Lung · China3Not yet recruitingDec 30, 20301,438
NCT07274813Advanced/Metastatic Solid Tumors · ChinaEarly 1RecruitingMar 30, 2027254

How it is read

Names in the registry

  • “Investigational drug: HLX37 dose1, IV, Q3W”, 1 entry
  • “Investigational drug: HLX37 dose2, IV, Q3W”, 1 entry
  • “HLX37”, 1 entry

Codes read as this program: HLX37.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.